"10.1371_journal.pone.0100812","plos one","2014-07-14T00:00:00Z","Steffen Wolfsgruber; Michael Wagner; Klaus Schmidtke; Lutz Frölich; Alexander Kurz; Stefanie Schulz; Harald Hampel; Isabella Heuser; Oliver Peters; Friedel M Reischies; Holger Jahn; Christian Luckhaus; Michael Hüll; Hermann-Josef Gertz; Johannes Schröder; Johannes Pantel; Otto Rienhoff; Eckart Rüther; Fritz Henn; Jens Wiltfang; Wolfgang Maier; Johannes Kornhuber; Frank Jessen","Department of Psychiatry, University of Bonn, Bonn, Germany; German Center for Neurodegenerative Diseases, Bonn, Germany; Center for Geriatric Medicine, Ortenau Klinikum, Offenburg-Gengenbach, Germany; Department of Gerontopsychiatry, Central Institute of Mental Health, Mannheim, Germany; Department of Psychiatry, Technical University of Munich, Munich, Germany; Department of Neurology, University of Aachen, Aachen, Germany; Department of Psychiatry, University of Göttingen, Göttingen, Germany; Department of Psychiatry, Ludwig Maximilian University, Munich, Germany; Department of Psychiatry, Charité Berlin, Campus Benjamin Franklin, Berlin, Germany; Department of Psychiatry, University of Hamburg, Hamburg, Germany; Department of Psychiatry and Psychotherapy, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany; Center for Geriatric Medicine and Gerontology, University of Freiburg, Freiburg, Germany; Department of Psychiatry, University of Leipzig, Leipzig, Germany; Department of Psychiatry, University of Heidelberg, Heidelberg, Germany; Institute of General Practice, University of Frankfurt, Frankfurt am Main, Germany; Department of Medical Informatics, University of Göttingen, Göttingen, Germany; Brookhaven National Laboratory, Upton, New York, United States of America; Department of Psychiatry University of Essen, Essen, Germany; Department of Psychiatry, Friedrich-Alexander-University Erlangen, Erlangen, Germany","Conceived and designed the experiments: SW FJ MW. Analyzed the data: SW FJ MW. Contributed reagents/materials/analysis tools: KS LF AK SS HH IH OP FR HJ CL MH HJG JS JP OR ER FH JW WM JK. Wrote the paper: SW FJ MW. Acquisition of data: KS LF AK SS HH IH OP FR HJ CL MH HJG JS JP OR ER FH JW WM JK. Critical revision of the manuscript for important intellectual content: SW MW FJ KS LF AK SS HH IH OP FR HJ CL MH HJG JS JP OR ER FH JW WM JK. Study supervision: MW FJ WM JK JW ER. Obtained funding: WM JW JK.","Klaus Schmidtke has obtained honoraria from Nutricia and Merz for participation in advisory board meetings, and from Merz for lectures and for the preparation of manuscripts. Lutz Frölich holds/has held a board membership in Eisai, Elan/Weyth, Eli Lilly, GE Health Care, Janssen-Cilag, Lundbeck, Merz Pharma, Novartis, Pfizer, Schering-Plough. He has received payment for consultancy, expert testimony, honorarium or travelling support from AstraZeneca, Merz Pharma, Myriad, Neurochem, Novartis, Pfizer, Schering-Plough, Apotex Inc. and has received a research grant from Novartis, Pfizer paid to his institution. Harald Hampel has received lecture honoraria and/or research grants and/or travel funding and/or participated in scientific advisory boards for several pharmaceutical companies including Boehringer-Ingelheim, BMS, Elan, Wyeth, Novartis, Eisai, Pfizer, Schwabe, Sanofi-Aventis, Roche Pharmaceuticals and Diagnostics, GE Healthcare, Astra-Zeneca, Avid, Eli Lilly and Company, Janssen-Cilag, Merz Pharmaceuticals, GSK-Bio, Jung-Diagnostics, Thermo Fisher Scientific Clinical Diagnostics B•R•A•H•M•S GmbH. He is co-inventor in the following pending patent submissions (“Method for predicting whether subjects with mild cognitive impairment (MCI) will develop Alzheimers disease”, PCT/US03/35516; “3-Hydroxykynurenin im Serum als diagnostischer Marker für die Demenz vom Alzheimer-Typ”, PCT/EP2006/002907; “Neurodegenerative markers for psychiatric conditions”, EP2006002907; “Ratio Aβ42/40 im Plasma in der Früh- und Differentialdiagnose der Alzheimer Krankheit”, IIIB8/823/06; “Liquordiagnostisches in vitro Verfahren zur Diagnose von Demenz-Erkrankungen und neuroinflammatorischen Erkrankungen”, PCT/EP2006007141; “In vitro Verfahren zur Diagnose von neurodegenerativen Erkrankungen”, PCT/EP2006007272; “In vitro Verfahren zur Diagnose und Frühdiagnose von neurodegenerativen Erkrankungen”, PCT/EP2007010331) and has received no royalties. Michael Hüll is PI in clinical studies from Pfizer Inc, Noscira Inc and Abbvie, has received a research grant from Schwabe GmbH, has received speakers honoraria from Pfizer Inc, Merz Pharmaceuticals, Glaxo Smith Kline and served on an advisory board for Hoffman La Roche. Johannes Pantel has received lecture honoraria from Merz, Janssen-Cilag, Novartis. Eckart Rüther is a Merz GmbH-collaborator, is on the speakers bureau of/has received a travel grant from BMS, Lundbeck, Servier and Otsouka and has received a research grant from Lilly, BMS, Astra-Zeneca and Lundbeck. Fritz Henn has been a consultant to Astra-Zeneca in the area of depression between June 2011 and November 2012. Jens Wiltfang is on the Advisory Board for Eli Lilly and has received consulting fee or honorarium and support for travelling to Board meetings. He received payment for lectures from Novartis and has received research grants from the EU and the German Federal Ministry of Education and Research paid to his institution for various research projects in some of which he served as coordinator. Wolfgang Maier has received a research grant from the German Federal Ministry of Education and Research paid to his institution and is on the speakers bureau/has received payment for educational lectures from Merz. Johannes Kornhuber has received grants from the BMBF (Bundesministerium für Bildung und Forschung) and the German Research Foundation (DFG). Furthermore, he has received financial support for conducting clinical trials from various pharmaceutical companiesmanufacturing anti-dementia drugs. He is mentioned as coinventor on the following patents: Substituted piperidines or pyrrolidine compounds for treating sigma-receptor modulated disorders (WO001996031208A3); Method of differentially diagnosing dementias (WO002008058764A1); Soluble amyloid precursor proteins in cerebrospinal fluid as biomarkers of Alzheimers disease (EP000002068151A1); Immunglobulin-bound Aβ and immunglobulins-binding Aβ peptides in diagnosis and therapy of Alzheimers disease (WO002007082750A1); Method of diagnosing acute cerebral ischemia (WO002008058764A1). Frank Jessen has received consultation board honoraria and speakers fees from AC Immune, Lilly, GE Healthcare, Janssen, USB, Schwabe, Esai, Pfizer, Novartis, Roche. He has received a research grant paid to his institution from Schwabe. This does not alter our adherence to PLOS ONE policies on sharing data and materials.","2014","07","Steffen Wolfsgruber","SW",23,TRUE,3,NA,3,3,TRUE,TRUE,FALSE,0,NA,FALSE
